Skip to main content

Novel Rx

      The risk of discontinuing first line biologics was twice higher in non-radiographic female patients compared to males. A

      Antoni Chan MD (Prof) synovialjoints

      10 months 3 weeks ago
      The risk of discontinuing first line biologics was twice higher in non-radiographic female patients compared to males. Abstr#0572 @RheumNow #ACR24 https://t.co/1tQUhsbqUu
      Dhir et al. RCT of increasing folic acid from 5-10mg per week to 15-35mg per week if MTX intolerance. No benefit! Althou

      Richard Conway RichardPAConway

      10 months 3 weeks ago
      Dhir et al. RCT of increasing folic acid from 5-10mg per week to 15-35mg per week if MTX intolerance. No benefit! Although significant placebo response and folic acid is relatively benign. @RheumNow #ACR24 Abstr#0525 https://t.co/D3yfV6a8t6 https://t.co/QpDa1alvMz
      Serrano-Combarro et al. Baricitinib in RA-ILD . 72 patient case series. PFTs in picture. HRCT stable/improved in 72% ove

      Richard Conway RichardPAConway

      10 months 3 weeks ago
      Serrano-Combarro et al. Baricitinib in RA-ILD . 72 patient case series. PFTs in picture. HRCT stable/improved in 72% over 24 months. Dyspnoea stable/improved in 90%. @RheumNow #ACR24 Abstr#0476 https://t.co/aVI2kRZkMN https://t.co/4l5GKsFKtm
      For many years glucocorticoids were the mainstay of our treatment of granulomatosis with polyangiitis (GPA). The paradigm shifted with cyclophosphamide and then again with rituximab, and we used less steroids, but we still used lots. Avacopan teased the demise of steroids, but in the trial they, and now we, still use them. Glucocorticoids are our old trusty friend, our comfort blanket. But no more! Good riddance to the medication with the
      🚨Therapeutic target in PsO?
      Abst#0067 from Cleveland Clinic evaluated pts w/ PsO at high risk for PsA (HR-PsO).
      - HR-

      Adela Castro AdelaCastro222

      10 months 3 weeks ago
      🚨Therapeutic target in PsO? Abst#0067 from Cleveland Clinic evaluated pts w/ PsO at high risk for PsA (HR-PsO). - HR-PsO: ⬆️percentage in migratory dendritic cells with elevated expression of CXCR4. - Migratory effect ⬇️ after selective CXCR4 inhibitor. #ACR24 @ElaineHusniMD… https://t.co/nVoAThUxi1 https://t.co/8d1K3nkttI
      Abstract 0587: Among PsA patients (bDMARD-naive & TNF non-responders) treated with Bimekizumab, better disease contr

      Akhil Sood MD AkhilSoodMD

      10 months 3 weeks ago
      Abstract 0587: Among PsA patients (bDMARD-naive & TNF non-responders) treated with Bimekizumab, better disease control was linked to improved work productivity, including ↓ work impairment, ↓ presenteeism, and ↓ activity impairment. #ACR24 @RheumNow https://t.co/sZBjJ9lk39
      Lots of ‘CARTS’, not enough ‘work horses’!

      There are now ~40 CAR-T protocols in #lupus incl many presentations

      Janet Pope Janetbirdope

      10 months 3 weeks ago
      Lots of ‘CARTS’, not enough ‘work horses’! There are now ~40 CAR-T protocols in #lupus incl many presentations at #ACR24 -most are uncontrolled -selection of pts is key. We need a pathway forward for reg approval & guidelines for studies! @RheumNow @ACRheum 18abst #OOO4 https://t.co/Mckwvn3Ffn
      Small but useful open label RCT of MMF vs CYC vs TAC in SLE nephritis

      Surprisingly similar rates of remission at week 2

      Mike Putman EBRheum

      10 months 3 weeks ago
      Small but useful open label RCT of MMF vs CYC vs TAC in SLE nephritis Surprisingly similar rates of remission at week 24... suggests TAC could be an option for induction? #ACR24 @RheumNow Abstr#0670 https://t.co/rO0ufturHW
      Upadacitinib (UPA), a new oral treatment option for GCA? Dr. Peter Merkel discusses SELECT-GCA.
      UPA15 + 26-week GC taper

      Jiha Lee JihaRheum

      10 months 3 weeks ago
      Upadacitinib (UPA), a new oral treatment option for GCA? Dr. Peter Merkel discusses SELECT-GCA. UPA15 + 26-week GC taper >> PBO with a 52-week GC taper for GCA remission. #ACR24 #ACRBest @RheumNow ABST#0770 https://t.co/UbQLVA8X7r
      It's been a wild ride over the last 20 years of RA b/tsDMARDs, and fascinating to see how our prescribing habits have ch

      David Liew drdavidliew

      10 months 3 weeks ago
      It's been a wild ride over the last 20 years of RA b/tsDMARDs, and fascinating to see how our prescribing habits have changed over that time. MarketScan data tell a story of fashion and fame. What will the next 20 years be like? #ACR24 ABST0509 @jeffsparks @RheumNow https://t.co/wCcWgkHrvc
      Major update in tx for GCA beyond Toci

      SELECT-GCA showed upadacitinib 15mg daily achieving higher rates of remission wi

      Brian Jaros, MD Dr_Brian_MD

      10 months 3 weeks ago
      Major update in tx for GCA beyond Toci SELECT-GCA showed upadacitinib 15mg daily achieving higher rates of remission with SHORTER (26wk) steroid use compared to placebo (52wk) No significant adverse safety signal w JAKi including MACE/malignancy @RheumNow #ACR24 Abstract 0770 https://t.co/45D0Txed2N
      GLP1ra is now part of GDMT, including pts without diabetes. The role of rheums in prescribing these remain to be seen. -

      TheDaoIndex KDAO2011

      10 months 3 weeks ago
      GLP1ra is now part of GDMT, including pts without diabetes. The role of rheums in prescribing these remain to be seen. - Dr Weber #ACR24 @rheumnow @ACRheum https://t.co/U9XEhGBXBN
      #0509
      📊 RA DMARD Trends in US (2001-2021)

      🧑‍🤝‍🧑 407,728 DMARD starts in 229,365 patients

      📉 csDMARD

      Caoilfhionn Connolly CaoilfhionnMD

      10 months 3 weeks ago
      #0509 📊 RA DMARD Trends in US (2001-2021) 🧑‍🤝‍🧑 407,728 DMARD starts in 229,365 patients 📉 csDMARD use fell (79.7% → 54.7%) ‼️Methotrexate dropped 29% → 15% 📈 bDMARDs (20.3% →33.1%),tsDMARDs (0.1% → 12.2%) both ⬆️⬆️ 💊Biosimilar uptake low #ACR24 @RheumNow @jeffsparks https://t.co/JepaWj7azY
      The TAPIR Trial on GPA shows higher (15.5%) relapse in the 0 mg prednisone arm vs. 4.2% in the 5 mg arm (OR 4.22), but d

      Antoni Chan MD (Prof) synovialjoints

      10 months 3 weeks ago
      The TAPIR Trial on GPA shows higher (15.5%) relapse in the 0 mg prednisone arm vs. 4.2% in the 5 mg arm (OR 4.22), but does not impact PROs. Key finding: benefit of 5 mg/day seen only in non-rituximab regimens (20% vs. 2.6%, OR 9.50). Abstr#0774 Plenary 1 @RheumNow #ACR24… https://t.co/5DjW5Zwh0J https://t.co/UnsVPzJfs6
      SELECT-GCA: Upa in GCAMerkelUpa 15 mg v 7.5 v PBO w slower GC taper70% new onset, 30% relapse. Few prev on IL6Primar

      Eric Dein ericdeinmd

      10 months 3 weeks ago

      SELECT-GCA: Upa in GCA Merkel Upa 15 mg v 7.5 v PBO w slower GC taper 70% new onset, 30% relapse. Few prev on IL6 Primary endpt: sustained remission at w52- UPA 15 mg beats PBO (p=0.0019) 34% relapse in UPA vs 60% PBO Less steroids, longer time to flare @RheumNow #ACR24 #ACRBest https://t.co/1OV2889Ny0

      ×